US-Listed In Vitro & In Vivo Diagnostic Substances — Revenue Percentiles, FY 2025

Population: 16 US-listed companies (SIC 2835), fiscal year 2025; fiscal year ends 2025-12-28 to 2026-05-31.

Fiscal year: 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · latest

10th percentile	$1.6M
25th percentile	$4.4M
Median	$18.4M
75th percentile	$836.0M
90th percentile	$2.1B
Mean	$652.6M
Minimum	$14.8k
Maximum	$4.3B

Methodology & sources
Revenue as filed, one fiscal year per company; percentiles computed in the database via percentile_cont, never by a model. Fiscal year 2025 = fiscal years ending 2025-06-01 to 2026-05-31 (majority-overlap rule; June-ending fiscal years count toward the ending calendar year).
Source: SEC EDGAR filings (public domain). Data: FACTANKER registry, precomputed 2026-09-03.

Evidence samples

Latest Revenue percentiles (live) · All In Vitro & In Vivo Diagnostic Substances benchmarks · All industries

Cite as: FACTANKER, https://factanker.com/industries/sic-2835/revenue/2025